相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Patient-Derived Non-Muscular Invasive Bladder Cancer Xenografts of Main Molecular Subtypes of the Tumor for Anti-Pd-l1 Treatment Assessment
Ekaterina Blinova et al.
CELLS (2019)
Biological significance of GATA3, cytokeratin 20, cytokeratin 5/6 and p53 expression in muscle-invasive bladder cancer
Chung-Chieh Wang et al.
PLOS ONE (2019)
PD-L1 Immunohistochemistry Assay Concordance in Urothelial Carcinoma of the Bladder and Hypopharyngeal Squamous Cell Carcinoma
Anjelica Hodgson et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2018)
PD-L1 expression in tumor cells and the immunologic milieu of bladder carcinomas: a pathologic review of 165 cases
Jonathan J. Davick et al.
HUMAN PATHOLOGY (2018)
PD-1 and PD-L1 are more highly expressed in high-grade bladder cancer than in low-grade cases: PD-L1 might function as a mediator of stage progression in bladder cancer
Takashi Kawahara et al.
BMC UROLOGY (2018)
High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients
Johannes Breyer et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review
Viktor Soukup et al.
EUROPEAN UROLOGY (2017)
Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications
Stephanie A. M. Wankowicz et al.
JOURNAL OF UROLOGY (2017)
Effects of programmed death-ligand 1 expression on OK-432 immunotherapy following transurethral resection in non-muscle invasive bladder cancer
Zhi-Hua Liu et al.
ONCOLOGY LETTERS (2017)
PD-L1 expression in bladder cancer and metastasis and its influence on oncologic outcome after cystectomy
Renate Pichler et al.
ONCOTARGET (2017)
Atezolizumab: A novel PD-L1 inhibitor in cancer therapy with a focus in bladder and non-small cell lung cancers
A. Krishnamurthy et al.
DRUGS OF TODAY (2017)
Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
Christophe Massard et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Anti-PD-L1 inhibitor durvalumab in bladder cancer
Vicki Brower
LANCET ONCOLOGY (2016)
Molecular and Cellular Characterization of Human CD8 T Suppressor Cells
Zheng Xu et al.
FRONTIERS IN IMMUNOLOGY (2016)
Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use
Vipulkumar Dadhania et al.
EBIOMEDICINE (2016)
Bladder Cancer Molecular Taxonomy: Summary from a Consensus Meeting
Seth P. Lerner et al.
BLADDER CANCER (2016)
Management of noninvasive bladder cancers
John B. Eifler et al.
CURRENT OPINION IN ONCOLOGY (2015)
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
Sandip Pravin Patel et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy
Woonyoung Choi et al.
CANCER CELL (2014)
Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder
E. Xylinas et al.
EJSO (2014)
The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies
Li Shi et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
T-cell coregulatory molecule expression in urothelial cell carcinoma: Clinicopathologic correlations and association with survival
Stephen A. Boorjian et al.
CLINICAL CANCER RESEARCH (2008)
Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers
Juro Nakanishi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion
Christian Blank et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
分享论文
